Please login to the form below

Not currently logged in
Email:
Password:

Xultophy

This page shows the latest Xultophy news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Novo Nordisk preps for speedy oral GLP-1 drug filing

10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone.

Latest news

More from news
Approximately 13 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics